Abbott Laboratories shares drop almost 2% after ongoing operational challenges and partnership announcement

Traders Union
All News
Stocks
Abbott Laboratories slides 1.82% today

Highlights

Abbott Laboratories will pay a quarterly dividend of 63 cents per share as of September 2026.
Abbott expanded its collaboration with Berry Street to provide tailored nutrition support through its Lingo glucose monitoring platform, amid higher competition and ongoing challenges in nutrition.
Shares of Abbott traded below key moving averages with sustained downside momentum, remaining under pressure between $100.12 to $103.1 for the next five days.

Dividend and partnership news offset by persistent selling on competition fears

Abbott Laboratories announced a quarterly common dividend of 63 cents per share as of September 2026. The company expanded its partnership with Berry Street to offer personalized nutrition support via its Lingo glucose monitoring platform. Reports also cited increased segment competition and ongoing operational challenges in its nutrition business, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes ongoing weakness in Abbott Laboratories due to fierce competition and underperformance in the nutrition segment. He highlights the persistent technical breakdown, with price action stuck below key moving averages and momentum indicators confirming the prevailing bearish bias. The dividend announcement and partnership offer limited upside given the broader operational challenges. Kharitonov warns that the risk of further downside is elevated, as structural recovery signals are absent. "Sustained selling pressure and weak demand participation mean any rallies may be short-lived in the current setup."

Viktoras Karapetjanc, expert at Traders Union, sees the dividend announcement and strategic partnership as positive signals for Abbott’s long-term value. He believes broad market conditions and operational challenges have temporarily overshadowed the stock's underlying strengths. Karapetjanc notes that the bullish 50-day and 200-day average alignment reflects a resilient structure. "The market offers new opportunities as foundational metrics remain strong — I expect a reversal with further growth potential once sentiment shifts."

Parshwa Turakhiya, analyst, observes that Abbott Laboratories’ short-term sentiment is heavy, with price hugging support near $101.57. He points out that oversold technical readings may trigger a brief relief bounce even as resistance at $103.1 caps upside. Turakhiya highlights that news flow has not shifted sentiment, so sideways or breakdown scenarios are more likely. "If $101.57 fails, a drop toward $100.12 could attract dip-buyers looking for a sentiment-driven rebound."

Sustained downside momentum as key technical levels fail to hold

Abbott Laboratories is currently trading below its 20-day, 50-day, and 200-day moving averages ($106.16, $106.71, and $104.87, respectively), confirming persistent downward pressure across short, medium, and long-term timeframes. The prevailing trend is bearish, with resistance at $103.1 and immediate support at $101.57. The long-term alignment of the 50-day versus the 200-day average remains bullish. Momentum readings are weak, as both MACD and ADX point to further downside. The RSI and CCI indicate an oversold condition, while Stochastic RSI is neutral. Bull/Bear Power (BBP) shows buyers have a marginal edge, but the overall picture remains pressured. The stock last traded at $101.61, near the session low, after opening with a small upside gap and experiencing low intraday volatility, underscoring the sustained negative tone.

Earlier, analysts noted that Abbott Laboratories faced persistent technical weakness, with continued downside momentum dominating price action. The current breakdown adds further evidence to this negative trend, and traders should closely monitor the $101.57 support, as a sustained breach could trigger additional declines toward the next volatility band near $100.12.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.